ProCE Banner Activity

Acalabrutinib Monotherapy in Hematologic Malignancies: Updated Safety and Efficacy Results

Slideset Download
Conference Coverage
Extended follow-up data from multiple studies confirm significant efficacy and tolerability of acalabrutinib in CLL and other B-cell malignancies.

Released: June 03, 2020

Expiration: June 02, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono